Chemistry: molecular biology and microbiology – Vector – per se
Patent
1998-09-16
2000-04-04
Degen, Nancy
Chemistry: molecular biology and microbiology
Vector, per se
536 234, 536 235, 536 2353, C12N 1512, C12N 1513, C12N 1562, C12N 1585
Patent
active
060460474
ABSTRACT:
Dimerization and oligomerization of proteins are general biological control mechanisms that contribute to the activation of cell membrane receptors, transcription factors, vesicle fusion proteins, and other classes of intra- and extracellular proteins. We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins. In principle, any two target proteins can be induced to associate by treating the cells or organisms that harbor them with cell permeable, synthetic ligands. To illustrate the practice of tis invention, we have induced: (1) the intracellular aggregation of the cytoplasmic tail of the .zeta. chain of the T cell receptor (TCR)-CD3 complex thereby leading to signaling and transcription of a reporter gene, (2) the homodimerization of the cytoplasmic tail of the Fas receptor thereby leading to cell-specific apoptosis (programmed cell death) and (3) the heterodimerization of a DNA-binding domain (Gal4) and a transcription-activation domain (VP16) thereby leading to direct transcription of a reporter gene. Regulated intracellular protein association with our cell permeable, synthetic ligands offers new capabilities in biological research and medicine, in particular, in gene therapy. Using gene transfer techniques to introduce our artificial receptors, one can turn on or off the signaling pathways that lead to the overexpression of therapeutic proteins by administering orally active "dimerizers" or "de-dimerizers", respectively. Since cells from different recipients can be configured to have the pathway overexpress different therapeutic proteins for use in a variety of disorders, the dimerizers have the potential to serve as "universal drugs". They can also be viewed as cell permeable, organic replacements for therapeutic antisense agents or for proteins that would otherwise require intravenous injection or intracellular expression (e.g., the LDL receptor or the CFTR protein).
Belshaw Peter
Crabtree Gerald R.
Ho Steffan N.
Schreiber Stuart L.
Spencer David M.
Berstein David L.
Board of Trustees of Leland Stanford Jr. University
Clauss Isabelle M.
Degen Nancy
President and Fellows of Harvard College
LandOfFree
Regulated transcription of targeted genes and other biological e does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Regulated transcription of targeted genes and other biological e, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Regulated transcription of targeted genes and other biological e will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-364285